Pharmaceuticals & Biopharmaceuticals

PLYMOUTH MEETING – November 03, 2026 -- INOVIO (NASDAQ: INO) will present its INO-D001 program for Hemophilia A at the World Federation of Hemophilia New Technology & Gene Therapy (NTGT) Workshop in Montreal on Thursday, Nov. 12, extending its DNA medicine work beyond HPV-related diseases, cancer and infectious diseases.

INOVIO schedules rare disease presentation in New York for Nov. 8

The company will speak at the Soft Bones Third International Scientific Meeting on Hypophosphatasia in New York on Sunday, Nov. 8. Its presentation is titled "Rare Disease Protein Replacement Therapeutics: The Transformational Potential of Next-Gen DNA Medicine."

Montreal workshop session focuses on INO-D001 for Hemophilia A

The Nov. 12 presentation at the WFH NTGT Workshop is dedicated to INO-D001 in Hemophilia A. The two appearances are four days apart, on Nov. 8 and Nov. 12.

BAD HOMBURG – – November 02, 2026 -- Fresenius has secured exclusive rights to up to 37 biosimilar candidates under a development agreement with WuXi Biologics. The company calls it the largest development agreement announced in the biosimilars industry to date. The deal could lift Fresenius' portfolio from 29 marketed and pipeline molecules today to as many as 66 over the next decade, addressing more than €370 billion in originator list-price-based sales.

Fresenius keeps full commercial economics and selection control

Fresenius will hold exclusive global commercialization rights, including marketing authorizations, and the full economics of each commercialized product. It will select and advance candidates against three criteria: market attractiveness, development risk and expected returns. Development is expected to run through WuXi Biologics' network across Europe, the United States, China and Singapore.

RALEIGH – November 02, 2026 -- RedHill Biopharma (NASDAQ: RDHL) said two independent in vitro studies confirmed that its Crohn's disease candidate RHB-204 kills Mycobacterium avium subspecies paratuberculosis (MAP) at a level comparable to RHB-104, which posted a 64% efficacy gain in a Phase 3 trial.

Two microbiology centers confirm MAP-killing in culture and phage assays

The studies used long-term intracellular culture and spot and phage assays. One was led by Professor Tim Bull of City St George's University of London. The other was led by Professor Irene Grant of Queen's University Belfast and Dr Hannah Dane, working with Rapid-myco Technologies.

SYDNEY – November 02, 2026 -- Kazia Therapeutics (NASDAQ: KZIA) will present two preclinical abstracts on its lead asset paxalisib at the San Antonio Breast Cancer Symposium (SABCS), held Dec. 8-11, 2026, in San Antonio, Texas.

Poster P4-9-18 challenges the view that dual PI3K/mTOR inhibitors are equivalent

The first poster reports that paxalisib induces durable tumour and immune reprogramming across breast cancer subtypes. Kazia says these effects are not necessarily shared by other dual PI3K/mTOR inhibitors in preclinical models. The company believes the evidence supports a mechanism of action that extends beyond conventional kinase inhibition.

NEW YORK – November 02, 2026 -- Nuvation Bio (NYSE: NUVB) will present four posters on safusidenib, its investigational mutant IDH1 inhibitor, at the Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia on November 12-15, 2026. One poster carries updated long-term Phase 2 J201 results that go beyond the topline data the company announced in July 2026.

Three trial-in-progress posters cover ongoing safusidenib studies

The other three posters give overviews of ongoing safusidenib trials. Nuvation Bio will staff Booth #126 at the meeting and plans to post the materials in the Publications section of its website after the presentations.

CEO David Hung said patients with IDH1-mutant glioma are often diagnosed in their 30s and 40s and need targeted treatments with "durable responses."

BOULDER – November 02, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) granted inducement stock options on 17,250 shares and restricted stock units covering 8,626 shares to two new non-executive employees on October 30, 2026.

Options carry a $38.90 exercise price set at the grant-date close

Each option has an exercise price of $38.90 per share, equal to Edgewise's closing share price on the grant date. The awards were made under the company's 2024 Inducement Equity Incentive Plan.

Options vest over four years, with a one-year cliff

Twenty-five percent of the shares under each option vest on the first anniversary of the employee's start date. The remainder vest in 1/48th monthly installments, subject to continued service.

JERSEY CITY – November 02, 2026 -- ABVC BioPharma (NASDAQ: ABVC) has closed a private placement of original issue discount senior convertible promissory notes that generated approximately $3.39 million in gross proceeds, before placement agent fees and offering expenses, WallachBeth Capital LLC announced.

Notes carry $4.1 million principal and a June 2027 maturity

The 17.5% OID Notes have an aggregate principal amount of $4,106,060 and mature on June 30, 2027. Investors in the securities purchase agreement are institutional and other accredited investors.

The notes become convertible into ABVC common stock after the eight-month anniversary of issuance. The conversion price is 85% of the average of the three VWAPs for the three trading days immediately before conversion, subject to a floor price and adjustments set out in the notes.

Warren – October 31, 2026 -- PTC Therapeutics (NASDAQ: PTCT) granted stock options on 9,620 shares and 11,535 restricted stock units to 13 new employees, with the options struck at $63.02 per share.

Compensation Committee approved the grants on Oct. 28 under Nasdaq's inducement exception

The awards were made under the Nasdaq inducement grant exception, Listing Rule 5635(c)(4). PTC describes them as material to each employee's decision to accept employment. The options are non-statutory.

Option exercise price is set at the $63.02 closing price on the grant date

The exercise price matches PTC's closing share price on Oct. 28, 2026. Each option has a 10-year term and vests over four years. A 25% tranche vests on the first anniversary of the employee's hire date. After that, 6.25% of the original share count vests at the end of each three-month period until fully vested. Vesting depends on continued service.

Shanghai – October 31, 2026 -- Shanghai Zhimeng Biopharma has completed enrollment of 255 patients in the pivotal Phase 2/3 trial of CB03-154 for amyotrophic lateral sclerosis (ALS), moving the potassium channel opener toward topline data and a possible new drug application in China.

Trial runs at 15 Chinese centers with a Week 39 primary endpoint

The study is led by Professor Fan Dongsheng of the 3rd Affiliated Hospital of Peking University and spans 15 clinical research centers in Mainland China. Its primary efficacy endpoint is the change from baseline in ALSFRS-R score at Week 39. China's Center for Drug Evaluation (CDE) cleared the Phase 2/3 study in July 2025. The U.S. FDA granted CB03-154 Orphan Drug Designation in October 2023.

Shelton – October 30, 2026 -- Intensity Therapeutics (Nasdaq: INTS) will report third-quarter 2026 financial results before the market opens on November 5, 2026, with management hosting a live webcast and conference call at 8:00 a.m. Eastern time to review the numbers and give a corporate update.

The quarter covers the period ended September 30, 2026. An archived webcast will be available for replay shortly after the call ends.

Phase 3 sarcoma trial is the late-stage anchor of the pipeline

The late-stage clinical biotech develops intratumoral cancer therapies. Its lead candidate, INT230-6, combines cisplatin and vinblastine sulfate with a penetration enhancer molecule called SHAO, which the company says disperses the drugs throughout tumors. The drug is injected directly into the tumor.